Moxolunic CF SR Tablet is a powerful dual-action antibiotic combination designed to treat a broad spectrum of bacterial infections. It contains two potent antimicrobials: Moxifloxacin, a fourth-generation fluoroquinolone, and Cefixime, a third-generation cephalosporin. Together, they offer enhanced efficacy against a wide range of Gram-positive and Gram-negative bacteria, making this formulation effective in treating respiratory tract infections and other systemic bacterial infections.
Moxifloxacin (400mg) inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair, resulting in bacterial cell death. It is highly effective against pathogens commonly involved in community-acquired respiratory infections, such as Streptococcus pneumoniae and Haemophilus influenzae.
Cefixime (400mg) disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. It is especially useful in treating infections of the upper and lower respiratory tract, urinary tract, and certain sexually transmitted infections.
This sustained-release (SR) formulation ensures a prolonged therapeutic effect, reducing the frequency of dosing while maintaining optimal plasma concentration. It is especially beneficial in improving patient compliance and therapeutic outcomes in cases of chronic or stubborn infections.